Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice

Age-related hearing loss (ARHL) is the most common sensory disabling condition associated with aging in humans. Yet, there are still no approved measures for preventing or treating this debilitating condition. With its slow progression, continuous and safe treatment approaches are critical for ARHL treatment. Nicotinamide Riboside (NR), a NAD+ precursor, is well-tolerated even for long-term use and is already shown effective in various disease models including Alzheimer's and Parkinson's Disease. However, its beneficial impact on ARHL is not known. In this study, we investigated transcriptomic profile in the cochlea of the mice (mtKeima strain) that are treated with NR for 10 months vs. non-treated. Overall design: NR administration to mtKeima mice started at 2 months and treatment lasted for 10 months until mice were 12 months of age. The cochlea was dissected for further gene expression profiling at the end of the NR administration.